ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
MaxCyte, Inc. (MXCT) stock declined over -2.11%, trading at $2.56 on NASDAQ, down from the previous close of $2.61. The stock opened at $2.53, fluctuating between $2.53 and $2.68 in the recent session.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Employees | 114 |
Beta | 1.21 |
Sales or Revenue | $41.29M |
5Y Sales Change% | 0.228% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Devices |